CVS Health (NYSE:CVS) Director Sells $34,619,673.90 in Stock

CVS Health Corporation (NYSE:CVS) Director Larry Robbins sold 370,462 shares of the business’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the transaction, the director directly owned 4,824,799 shares of the company’s stock, valued at $450,877,466.55. The trade was a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Larry Robbins also recently made the following trade(s):

• On Wednesday, May 20th, Larry Robbins sold 1,018,000 shares of CVS Health stock. The stock was sold at an average price of $93.82, for a total transaction of $95,508,760.00.
• On Tuesday, May 19th, Larry Robbins sold 1,983,538 shares of CVS Health stock. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10.

CVS Health Stock Performance

CVS Health stock traded up $0.07 during mid-day trading on Thursday, reaching $93.35. The company had a trading volume of 6,478,498 shares, compared to its average volume of 8,694,289. The company has a 50 day moving average of $79.69 and a 200-day moving average of $78.87. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $98.43. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The firm has a market cap of $119.11 billion, a price-to-earnings ratio of 41.12, a PEG ratio of 0.92 and a beta of 0.60.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, sell-side analysts expect that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Thursday, April 23rd. CVS Health’s payout ratio is 117.18%.

Analyst Upgrades and Downgrades

A number of research firms have commented on CVS. Leerink Partners restated an “outperform” rating and issued a $98.00 price target on shares of CVS Health in a research report on Thursday, March 5th. JPMorgan Chase & Co. raised their price target on CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Bank of America dropped their price target on CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a report on Tuesday, January 27th. DA Davidson upped their price target on shares of CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, Robert W. Baird upped their price target on shares of CVS Health from $92.00 to $94.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 15th. Twenty-two analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, CVS Health currently has an average rating of “Moderate Buy” and a consensus target price of $98.68.

Hedge Funds Weigh In On CVS Health

Several institutional investors have recently modified their holdings of the stock. Norges Bank acquired a new stake in CVS Health in the 4th quarter valued at approximately $1,666,265,000. Wellington Management Group LLP grew its position in CVS Health by 193.2% during the fourth quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock worth $1,473,270,000 after buying an additional 12,233,675 shares in the last quarter. Amundi raised its holdings in CVS Health by 95.3% in the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock valued at $572,665,000 after acquiring an additional 3,637,943 shares in the last quarter. Capital Research Global Investors grew its holdings in shares of CVS Health by 24.5% during the 3rd quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock worth $864,667,000 after purchasing an additional 2,253,531 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of CVS Health by 70.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 5,294,134 shares of the pharmacy operator’s stock worth $399,125,000 after purchasing an additional 2,188,307 shares during the period. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Glenview Capital publicly praised CVS Health’s progress, saying its concentrated position has returned 80% since May 2024 and highlighting the company’s ongoing turnaround, which may reinforce bullish investor sentiment. Glenview Capital Issues Statement on CVS Health
• Positive Sentiment: CVS also continued to announce community-focused initiatives, including senior affordable housing in New Jersey and programs supporting military families and maternal mental health, which may modestly support its reputation but are unlikely to move the stock on their own. CVS Health, Diocese of Camden, and The Walters Group Unite to Bring Senior Affordable Housing to Williamstown, New Jersey
• Neutral Sentiment: Additional company-newsroom items on maternal mental health, military support, and Aetna Better Health’s food-access program are positive from a branding standpoint, but they appear mostly promotional and have limited direct financial impact. Aetna Better Health of Louisiana Collaborates With Goodr To Launch Mobile Food Market and Chronic Care Program
• Negative Sentiment: Two hospital systems accused CVS of profiting from a “secret pricing scheme” tied to the federal 340B drug discount program, with combined alleged damages above $60 million. The lawsuits add legal, financial, and reputational risk, which could weigh on the shares. CVS Health Lawsuits Test 340B Practices And Investor Risk Assessment

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.